19 results about "Cardiac resynchronization therapy" patented technology

Implantable medical device for stimulating a heart includes a proximal electrode pole, and first and second distal electrode poles. During operation, the device performs: a) detecting an intrinsic atrial contraction of the heart; b) detecting an intrinsic ventricular contraction of the heart; c) determining a first intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction detected with the first distal electrode pole; and determining a second intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and iii) the intrinsic ventricular contraction detected with the second distal electrode pole; d) setting a stimulated atrioventricular conduction time for stimulating the ventricle of the heart with the first and / or second distal electrode poles, the stimulated atrioventricular conduction time being shorter than the shorter of the first and second intrinsic atrioventricular conduction times.

In some examples, a system can be used for delivering cardiac resynchronization therapy (CRT). The system may include a pacing device configured to be implanted within a patient. The pacing device can include a plurality of electrodes, signal generation circuitry configured to deliver ventricular pacing via the plurality of electrodes, and a sensor configured to produce a signal that indicates mechanical activity of the heart. Processing circuitry can be configured to identify one or more features of a cardiac contraction within the signal, and determine whether the contraction was a fusion beat based on the one or more features.

A system for providing for a cardiac resynchronization therapy comprises an implantable medical device (1) comprising a generator device (10) having a processing circuitry (100) for controlling operation of the generator device (10). The implantable medical device (1) is configured to be selectively connected to a left-ventricular coronary sinus electrode lead (12) configured for implantation on the left ventricle (LV) through the coronary sinus (CS) or to a left bundle branch electrode lead (13) configured for implantation on the cardiac septum (M) to engage with the conductive structure of the left bundle branch (LBB). A configuration unit (2, 4) has a user interface (20) to modify a configuration of the implantable medical device (1). The user interface (20) is user-actuatable to select a first mode or a second mode out of at least two modes for configuring the implantable medical device (1), wherein in the first mode a first set of parameters is pre-selected or user-selectable for configuring the implantable medical device (1) to function with the left-ventricular coronary sinus electrode lead (12) and in the second mode a second set of parameters is pre-selected or user-selectable for configuring the implantable medical device (1) to function with the left bundle branch electrode lead (13).

The present disclosure pertains to cardiac pacing methods and systems, and, more particularly, to cardiac resynchronization therapy (CRT). In particular, the present disclosure pertains to determining whether a patient is experiencing atrial fibrillation (AF). If the patient is experiencing AF, the efficacy of CRT is determined. A signal is sensed in response to a ventricular pacing stimulus. Through signal processing, a number of features are parsed from the signal and a determination is made as to whether the ventricular pacing stimulus evoked a response from the ventricle.

In some examples, a system can be used for delivering cardiac resynchronization therapy (CRT). The system may include a pacing device configured to be implanted within a patient. The pacing device can include a plurality of electrodes, signal generation circuitry configured to deliver ventricular pacing via the plurality of electrodes, and a sensor configured to produce a signal that indicates mechanical activity of the heart. Processing circuitry can be configured to identify one or more features of a cardiac contraction within the signal, and determine whether the contraction was a fusion beat based on the one or more features.

A method includes determining whether electrical activity is indicative of atrial fibrillation, determining whether mechanical activity is indicative of atrial fibrillation, and adjusting a pacing parameter or mode based on whether the electrical activity and the mechanical activity are indicative of atrial fibrillation. The electrical activity may be detected based on a far-field measurement. The method may be performed using a leadless implantable medical device.

To provide a technology for increasing the probability of improvement of cardiac asynchrony by a cardiac resynchronization therapy.SOLUTION: An electrostimulator includes: an electrode for giving electrostimulation to the ventricular muscle of the target heart to which electrostimulation is given in a cardiac resynchronization therapy; a cover covering at least a part of the target heart and the electrode; and an application circuit control part for controlling operation of an application circuit applying voltage or current to the electrode on the basis of information indicating timing at which stimulation is given to an optimum stimulus point being a position of the target heart where electrostimulation is given in the cardiac resynchronization therapy. Control by the application circuit control part controls the application circuit so that voltage or current is applied to the electrode disposed at the optimum stimulus point at the timing, and at least a part of the optimum stimulus point is covered with the cover.SELECTED DRAWING: Figure 1

A method executed by one or more computing systems involves accessing a cardiogram from a patient, determining an apparent activation location, identifying a pacemaker configuration, creating a visual representation of the patient's heart, marking the apparent activation location on the visual representation, displaying the marked visual representation of the heart, and providing an output indicating the pacemaker configuration.

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

A method executed by one or more computing systems involves accessing a cardiogram from a patient, determining an apparent activation location, identifying a pacemaker configuration, creating a visual representation of the patient's heart, marking the apparent activation location on the visual representation, displaying the marked visual representation of the heart, and providing an output indicating the pacemaker configuration.

The present technology is generally directed to implantable medical device systems configured to provide cardiac resynchronization therapy. In some embodiments, the implantable medical device system comprises a housing, electrodes carried by the housing, a transducer configured to produce input voltage signals in response to ultrasound energy, and a circuit configured to provide, via an electrical pathway, output voltage signals based on the input voltage signals. The circuit comprises a movable switch, and a slew rate detector configured to detect whether a voltage rate of an individual pulse of the input voltage signals exceeds a predetermined threshold voltage rate. The circuit is configured to move the switch to an open position in response to the detected voltage rate exceeding the predetermined threshold voltage rate.

In some examples, controlling delivery of cardiac resynchronization therapy (CRT) includes storing, in a memory of an implantable medical device system and in association with each of a plurality of heart rates, at least one respective value for an interval between an atrial event and a ventricular event. Processing circuitry of the implantable medical device system may determine a heart rate of a patient and select one of the stored values for the interval between the atrial event and the ventricular event associated with the determined heart rate. The processing circuitry may further determine whether to control therapy delivery circuitry of the implantable medical device system to deliver fusion pacing or biventricular pacing, based on the selected one of the stored values for the interval between the atrial event and the ventricular event.

The present technology generally includes devices, systems, and methods for providing electrical stimulation to the left ventricle of a human heart in a patient suffering from Left Bundle Branch Block (LBBB). In particular, the present technology includes an implantable receiver-stimulator and an implantable controller-transmitter for leadless electrical stimulation of the heart. The receiver-stimulator can include one or more sensors capable of detecting the electrical conduction of the heart and the receiver-stimulator can be configured to pace the stimulation of the left ventricle based off the sensed electrical conduction to achieve synchronization of the left and right ventricles.

The illustrative systems, devices, and methods described herein may be configured to deliver and adjust atrioventricular (AV) node stimulation to regularize a patient's heart rate and slow down, or decrease, the patient's heart and to deliver pacing therapy (e.g., cardiac resynchronization therapy, left ventricle only pacing therapy, biventricular pacing therapy, left bundle branch pacing therapy, etc.) in cooperation with the AV node stimulation.

The present technology is generally directed to implantable medical device systems configured to provide cardiac resynchronization therapy. In some embodiments, the implantable medical device system comprises a housing, electrodes carried by the housing, a transducer configured to produce input voltage signals in response to ultrasound energy, and a circuit configured to provide, via an electrical pathway, output voltage signals based on the input voltage signals. The circuit comprises a movable switch, and a slew rate detector configured to detect whether a voltage rate of an individual pulse of the input voltage signals exceeds a predetermined threshold voltage rate. The circuit is configured to move the switch to an open position in response to the detected voltage rate exceeding the predetermined threshold voltage rate.

The invention relates to an implantable medical device for stimulating a human or animal heart that comprises a single electrode (20) comprising a proximal electrode pole (213) designed and arranged to be implanted within an atrium (2) of the heart (1) to be stimulated and a distal electrode pole (203) designed and arranged to be implanted within the septum (13) of the heart (1) to be stimulated. During operation, the implantable medical device performs the following steps: a) detecting (500), with the proximal electrode pole (213), an intrinsic atrial contraction of the heart (1) to be stimulated or stimulating (500), with the proximal electrode pole (213), the atrium (2) of the heart (1) to be stimulated; b) detecting (530), with the distal electrode pole (203), an intrinsic ventricular contraction of the heart (1) to be stimulated; c) determining (530) an intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction; d) setting (550) a stimulated atrioventricular conduction time for stimulating the ventricle (3, 5) of the heart (1) to be stimulated with the distal electrode pole (203), the stimulated atrioventricular conduction time being shorter than the intrinsic atrioventricular conduction time.

An implantable medical device includes a plurality of electrodes to detect electrical activity, a motion detector to detect mechanical activity, and a controller to determine at least one electromechanical interval based on at least one of electrical activity and mechanical activity. The activity detected may be in response to delivering a pacing pulse according to an atrioventricular (AV) pacing interval using the second electrode. The electromechanical interval may be used to adjust the AV pacing interval. The electromechanical interval may be used to determine whether cardiac therapy is acceptable or whether atrial or ventricular remodeling is successful.

The invention relates to an implantable medical device for stimulating a human or animal heart, the device comprising a single electrode (20) comprising a proximal electrode pole (213) designed and arranged to be implanted within an atrium (2) of the heart (1) to be stimulated and a distal electrode pole (203) designed and arranged to be implanted within a septum (13) of the heart (1) to be stimulated. During operation, the implantable medical device performs the following steps: a) detecting (500) an intrinsic atrial contraction of the heart (1) to be stimulated with the proximal electrode pole (213) or stimulating (500) the atrium (2) of the heart (1) to be stimulated with the proximal electrode pole (213); b) detecting (530) an intrinsic ventricular contraction of the heart (1) to be stimulated with the distal electrode pole (203); c) determining (530) an intrinsic atrioventricular conduction time between i) the intrinsic atrial contraction or the stimulation of the atrium and ii) the intrinsic ventricular contraction; d) setting (550) a stimulated atrioventricular conduction time for stimulating a ventricle (3, 5) of the heart (1) to be stimulated with the distal electrode pole (203), the stimulated atrioventricular conduction time being shorter than the intrinsic atrioventricular conduction time.